Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Hemodynamic-GUIDEd Management of Heart Failure
NCT03387813 · View on ClinicalTrials.gov ↗
Study Summary
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
Conditions Studied
Interventions
- DEVICE CardioMEMS™ HF System
Study Locations (20)
California
- John Muir Medical Center — Concord
- Adventist Health St. Helena — Deer Park
- Scripps Health — La Jolla
- University of California at San Diego (UCSD) Medical Center — La Jolla
- USC University Hospital — Los Angeles
- Ronald Reagan UCLA Medical Center — Los Angeles
- Eisenhower Medical Center — Rancho Mirage
- Sutter Medical Center, Sacramento — Sacramento
- Mercy Medical Group - Cardiology — Sacramento
- San Diego Cardiac Center — San Diego
- California Pacific Medical Center - Van Ness Campus — San Francisco
- Ventura Cardiology Consultants — Ventura
Arizona
- Banner-University Medical Center Phoenix — Phoenix
- Arizona Cardiovascular Research Center — Phoenix
- Phoenix Cardiovascular Research Group — Phoenix
- University of Arizona — Tucson
Arkansas
- Washington Regional Medical Center — Fayetteville
- Baptist Health Medical Center — Little Rock
- Arkansas Heart Hospital — Little Rock
Colorado
- University of Colorado Hospital — Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,358 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-05-17 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387813
The ClinicalTrials.gov registry entry for NCT03387813 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which CardioMEMS™ HF System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03387813 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03387813 about?
NCT03387813 is a clinical study titled "Hemodynamic-GUIDEd Management of Heart Failure". The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
What is the current status of trial NCT03387813?
This trial is currently completed. It is a NA study. The enrollment target is 2,358 participants. The study started on 2018-03-15. Estimated completion is 2023-05-17.
What conditions does trial NCT03387813 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure, Diastolic, Heart Failure, Systolic, Heart Failure With Normal Ejection Fraction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03387813?
The interventions under investigation include: CardioMEMS™ HF System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03387813?
This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03387813 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.